Professionals 124 results
Capabilities 39 results
Industry
Industry
Industry
Experience 39 results
Experience
|January 8, 2026
$2.75 Billion Constellation Energy Generation, LLC Public Offering of Senior Notes
Experience
|September 22, 2025
Winston Paris advised the founders and shareholders of Bylaw, on its acquisition by Septeo
Experience
|September 4, 2025
Winston Represents Altus Power in 234 MW Portfolio Acquisition
Insights & News 783 results
Non-Fungible Insights: Blockchain Decrypted
|March 13, 2026
|7 Min Read
The close of 2025 highlighted the continuing momentum for the digital asset industry, with regulatory developments accelerating rather than slowing.
Recognitions
|March 10, 2026
|1 Min Read
Winston Recognized During Global Banking & Markets Awards: Latin America & Caribbean 2026
Client Alert
|March 9, 2026
|3 Min Read
On January 27, 2026, the U.S. Department of Health and Human Services Office of Inspector General (the OIG) issued a Special Advisory Bulletin (the Bulletin) addressing the application of the federal anti-kickback statute (the AKS) to direct-to-consumer (DTC) prescription drug sales.
The Bulletin, the OIG’s first Special Advisory Bulletin since September 2014, was issued in response to the proliferation of DTC programs. The Bulletin, which sets forth the framework under which a manufacturer’s DTC program presents a low risk of violating the AKS, is viewed by the growing DTC industry as favorable guidance. DTC programs offering modern weight-loss medications, such as GLP-1 drugs, are becoming increasingly popular, and the Bulletin provides a helpful framework to support the viability of these programs.
Other Results 30 results
Site Content
Law Glossary
Site Content


